Keyphrases
Atypical Carcinoid
53%
Lung Neuroendocrine Neoplasms
44%
Overall Survival
43%
Recurrence-free Survival
35%
Resection
32%
Video-assisted Thoracoscopic Surgery
31%
Typical Carcinoid
29%
Large Cell Neuroendocrine Carcinoma (LCNEC)
26%
Single Center
24%
Mitotic Count
22%
SUVmax
22%
Reoperation
22%
Lung
22%
Pulmonary Neuroendocrine Carcinoma
22%
SUVmean
22%
Standardized Uptake Value
22%
Nodal Involvement
22%
Ki-67 Index
22%
Lung Volume Reduction Surgery
22%
Fluorine-18-fluorodeoxyglucose Positron Emission Tomography
22%
Leber Hereditary Optic Neuropathy
22%
Ophthalmoplegia
22%
Acute Liver Failure
22%
Long-term Recurrence
22%
Exercise Intolerance
22%
Cirrhosis
22%
Long-term Survival
22%
Multiple acyl-CoA Dehydrogenase Deficiency
22%
Surgical Management
22%
Rare Cause
22%
Pulmonary Carcinoid
22%
Typical Lung Carcinoid
22%
Carcinoma Cells
14%
Adjuvant Therapy
14%
Small Cell Lung Carcinoma
14%
30-day Mortality
13%
Prognostic Factors
13%
Confidence Interval
12%
Peripapillary Retinal Nerve Fiber Layer (pRNFL)
11%
Lymph Node
9%
Primary Tumor
9%
Prognostic Biomarker
9%
Lung Sparing
8%
Consecutive Patients
8%
Surgical Resection
8%
Overall Survival Rate
8%
Surgery Approach
8%
Time-dependent Receiver Operating Characteristic Curve
7%
Older Men
7%
Lung-sparing Surgery
7%
Medicine and Dentistry
Carcinoid
100%
Surgery
64%
Recurrent Disease
54%
Neuroendocrine Tumor
49%
Large Cell Neuroendocrine Carcinoma
42%
Overall Survival
42%
Video-Assisted Thoracoscopic Surgery
29%
Recurrence Free Survival
27%
Pneumonectomy
26%
Radical Resection
26%
Fluorine-18
22%
Cohort Analysis
22%
Long Term Survival
22%
Standardized Uptake Value
22%
Glutaric Acidemia Type 2
22%
Positron Emission Tomography
22%
Fluorodeoxyglucose
22%
Acute Liver Failure
22%
Reoperation
22%
Liver Cirrhosis
22%
Ophthalmoparesis
22%
Exercise Intolerance
22%
Lung
22%
Recurrence Risk
22%
Biological Marker
16%
Lymph Node
16%
Primary Tumor
16%
Survival Rate
16%
Adjuvant Therapy
14%
Small Cell Lung Cancer
14%
Hazard Ratio
13%
Prognostic Factor
11%
Odds Ratio
11%
Liver Disease
11%
Proportional Hazards Model
11%
Kaplan Meier Method
10%
Injury
7%
Steatosis
7%
Systemic Therapy
7%
Diagnosis
7%
Skeletal Muscle
7%
Mitochondrial DNA
7%
Non Small Cell Lung Cancer
5%